What Osteoboost does

Osteoboost Health, Inc. (formerly Bone Health Technologies) is a US-based medical device company that markets the first FDA-cleared, non-drug prescription wearable therapy for osteopenia in postmenopausal women. Its core product is a Class II belt worn around the hips for 30 minutes a day, delivering patented, dynamically-calibrated low-magnitude, high-frequency (20-40 Hz, 0.1-0.3 g) mechanical vibration targeted to the lumbar spine and hips. Embedded force sensors at the iliac crest auto-adjust output to deliver a precise therapeutic dose, and an iOS companion app guides setup, captures session data, and tracks steps and calcium intake. The clinical foundation is a 12-month, randomized, double-blind, sham-controlled NIH-funded pivotal trial in 126 postmenopausal women that showed 85% reduction in vertebral bone density loss, 83% reduction in vertebral bone strength loss, and 55% reduction in hip bone density loss versus sham among per-protocol users, with 82% adherence and no device-related serious adverse events.

Osteoboost sells direct-to-consumer at a $995 special launch price (MSRP $1,500) through its own e-commerce storefront, with prescriptions routed to partner pharmacy HealthWarehouse for fulfillment and telehealth access to prescriptions provided via Beluga Health for $30 per consultation. The device is currently self-pay (HSA/FSA eligible with prescription) with no insurance or Medicare coverage. Every device includes a 2-year limited warranty, 30-day money-back guarantee, and one year free access to the Wellen by Osteoboost personalized exercise program (acquired July 2024). Distribution is U.S.-only; over 3,000 doctors across Mayo Clinic, Memorial Sloan Kettering, Harvard, Mount Sinai, Stanford, Emory, Brigham and Women's, and UCSD are actively prescribing the device. The company holds 6 issued US patents, is named a TIME Best Invention of 2025, and has raised approximately $15.75M in disclosed funding, most recently an $8M round led by Ambit Health Ventures in April 2026 to scale manufacturing, expand clinical research, and broaden commercial reach.

Name

Osteoboost

Legal name

Osteoboost Health, Inc.

Website

https://osteoboost.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Osteoboost Health, Inc. sells the first FDA-cleared, non-drug prescription wearable belt that uses targeted vibration therapy to slow bone loss in postmenopausal women with osteopenia. It distributes direct-to-consumer for $995 in the US via partner pharmacy HealthWarehouse and telehealth partner Beluga Health.

Ownership category

akta.pro rank

Product category

Wearable Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices) (HLAHAMAG)

Keywords

• Wearable medical devices
• Bone density therapy
• Osteoporosis prevention
• Vibration therapy
• Prescription medical devices

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Osteoboost device sales: One-time hardware sale of the Osteoboost vibration therapy belt at $995 special self-pay launch price (MSRP $1500). Each device ships free from partner pharmacy HealthWarehouse after prescription confirmation. Includes 2-year limited warranty, 30-day money-back guarantee, 1-year free access to the Wellen exercise program, and a companion iOS app.
2. Wellen by Osteoboost exercise program subscription: Subscription to the Wellen personalized exercise program (acquired from Wellen in 2024), included free for 1 year with device purchase ($114 standalone value). Gift cards can also be applied toward a Wellen subscription.
3. Osteoboost gift cards: E-gift cards redeemable toward an Osteoboost device purchase or a Wellen subscription.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Core offering

Osteoboost Health, Inc. (formerly Bone Health Technologies / BHT) develops and sells an FDA-cleared, prescription-only wearable vibration therapy belt for the treatment of osteopenia in postmenopausal women. The device delivers targeted low-magnitude, high-frequency mechanical stimulation to the lumbar spine and hips via an automated calibration system that senses contact force at the iliac crest and adjusts vibration output accordingly. The belt is paired with an iOS companion app that captures treatment data and is sold direct-to-consumer at premium pricing.

Product overview

Osteoboost Health, Inc. (formerly Bone Health Technologies) offers a single core medical device — the FDA-cleared Osteoboost precision vibration therapy belt — supported by an integrated ecosystem of companion services: the Osteoboost iOS companion app for session tracking and calibration feedback, the acquired Wellen by Osteoboost personalized exercise program (12 months free with every device), the Beluga Health telehealth prescription pathway, clinician resources for prescribers, and Osteoboost gift cards. The Osteoboost belt is the platform anchor, while the app, Wellen, and telehealth prescription service are tightly integrated add-on modules that together deliver the company's "360° Osteoboost experience" for postmenopausal women with osteopenia.

Differentiator

Problem solved

Functional benefit

Brands

• Wellen by Osteoboost: Personalized exercise program for osteoporosis and osteopenia; acquired July 2024 and now integrated as part of the Osteoboost ecosystem and companion app.

Products and services

• Osteoboost Wearable Vibration Therapy Belt
• Wellen by Osteoboost

Named customers8 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature5 records

Partnerships

Nine partnerships are on record, tiered core, minor and flagship.

• Midi HealthcoreGTM or Marketing Partner · 14 April 2026Osteoboost Health and Midi Health co-hosted a free public webinar on HRT and bone density for women in menopause on April 14, 2026 — a joint education and demand-generation initiative targeting the overlapping peri/menopausal and bone-health audience.
• AgeTech Collaborative™ from AARPminorStrategic or Co-development Partner · 24 October 2024Osteoboost joined the AgeTech Collaborative™ from AARP Accelerator Program on October 24, 2024, gaining access to AARP's ecosystem to scale solutions addressing age-related challenges including bone density loss.
• WellenflagshipStrategic or Co-development Partner · 25 July 2024Bone Health Technologies (now Osteoboost Health) acquired Brooklyn-based Wellen in July 2024 to integrate Wellen's personalized exercise-based osteoporosis care program with the Osteoboost vibration therapy belt. The combined offering pairs precision vibration therapy with the Wellen exercise program, which is bundled free for 1 year with every Osteoboost device purchase.
• HealthWarehouseflagshipChannel Partner/ Reseller/ DistributorHealthWarehouse (NPI: 1619252160; NCPDP#: 1832674) is Osteoboost Health's licensed partner pharmacy. Providers fax (1-888-870-2808), call (1-800-748-7001), or e-prescribe prescriptions to HealthWarehouse, which then fulfills and ships the Osteoboost device free to patients.
• Beluga HealthcoreImplementation/ SI/ Consulting PartnerBeluga Health is Osteoboost Health's telehealth partner that issues Osteoboost prescriptions online for $30 with no appointment or video visit required. The integration lets patients without a regular doctor still obtain a prescription quickly.
• University of Nebraska Medical Center (UNMC)flagshipStrategic or Co-development PartnerUNMC researchers conducted the 12-month, randomized, double-blind, sham-controlled pivotal clinical trial (126 postmenopausal women with osteopenia) that underpinned the FDA De Novo clearance. Dr. Laura Bilek (Associate Dean for Research, College of Allied Health Professions) serves as a scientific advisor and lead investigator.
• TheranovaflagshipStrategic or Co-development PartnerTheranova is the San Francisco medical device incubator founded by Dr. Dan Burnett (Osteoboost co-founder) that has spun out 14 companies and raised over $250M. Drs. Daniel Burnett and Michael Jaasma led Osteoboost's early development and secured research funding through Theranova.
• Apple App StorecoreTechnology or IntegrationOsteoboost's companion mobile app is distributed through the Apple App Store (iOS) and uses Apple iPhone/iPad pairing to guide device setup and calibration. Android version forthcoming.
• O.N. Diagnostics (VirtuOst)coreTechnology or IntegrationOsteoboost's pivotal clinical trial used VirtuOst (a software-only medical device from O.N. Diagnostics that analyzes CT scans to estimate vertebral bone strength and density) as the primary endpoint measurement. Dr. Tony Keaveny, VirtuOst's inventor, is a scientific advisor.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Marodyne Medical: Marodyne produces low-intensity vibration (LiV) therapy devices (Mediluv) clinically tested for improving bone density in postmenopausal women and older adults. It is the most direct competitor to Osteoboost, addressing the same osteopenia population with similar mechanical-vibration mechanism, though without Osteoboost's FDA De Novo clearance or wearable belt form factor.
• Power Plate International: Power Plate is the leading consumer/clinical whole-body vibration (WBV) platform brand, used by physical therapists, trainers, and consumers for muscle activation, circulation, and bone-health applications. It competes with Osteoboost for bone-health positioning but delivers vibration through the feet (whole-body) rather than targeted to the lumbar spine and hips, and is not FDA-cleared for osteopenia.
• Juvent Health: Juvent manufactures low-magnitude, high-frequency vibration platforms (originally developed from NASA research) marketed for bone density, balance, and musculoskeletal health. Like Osteoboost, it uses the same underlying low-magnitude vibration science inspired by astronaut bone-loss research and competes for the same postmenopausal low-bone-density patient population.

Emerging players

• Midi Health: Midi Health is a virtual care clinic specializing in perimenopause and menopause, with an overlapping patient population that experiences accelerated bone loss. Midi is an active Osteoboost GTM co-marketing partner (joint HRT/bone-density webinar, April 2026), making it both an adjacent competitor for women's midlife health and a meaningful distribution channel.
• Hinge Health: Hinge Health is a digital musculoskeletal care platform combining AI-guided exercise therapy, virtual PT, and pain-management coaching for back, joint, and women's health conditions. It overlaps with Osteoboost at the musculoskeletal / women's health intersection and represents a digital-first alternative channel that could either compete for patient mind-share or partner for cross-referral.
• AlterG: AlterG manufactures FDA-cleared anti-gravity treadmill systems used in physical therapy and rehabilitation clinics for post-injury, post-surgical, and musculoskeletal recovery. It shares the rehabilitation-equipment category with Osteoboost and is led by Gabriel Griego, Osteoboost's Head of Marketing — direct personnel and category overlap between the two companies.

Broad incumbents

• Bioventus: Bioventus is a publicly-traded orthobiologics and bone-health company with products including bone-graft substitutes, EXOGEN ultrasound bone-healing systems, and joint-pain therapies. As a broad incumbent in the bone-healing and recovery category, Bioventus is adjacent to Osteoboost's vibration therapy and could plausibly enter the osteopenia device space through acquisition or competing technology.
• Hologic: Hologic is the dominant manufacturer of DXA bone densitometers (Horizon/Discovery systems) used to diagnose osteopenia and osteoporosis — the diagnostic gateway that produces the patient population Osteoboost serves. As the incumbent in bone-health assessment, Hologic is a strategic adjacent player whose installed base of DXA scanners feeds Osteoboost's prescriber pipeline.
• Amgen: Amgen manufactures Prolia (denosumab) and Evenity (romosozumab), the leading injectable biologic drugs for osteoporosis and high-risk postmenopausal fracture patients. While not direct competitors (drug vs. device), they represent the pharmacological alternative Osteoboost displaces or complements in the treatment pathway between lifestyle and severe osteoporosis.
• GE HealthCare: GE HealthCare manufactures Lunar DXA bone densitometers, the other major installed base of bone-density diagnostic equipment alongside Hologic. As the diagnostic upstream of Osteoboost's prescription funnel, GE HealthCare shares the bone-health category and benefits from growing osteopenia awareness that drives Osteoboost adoption.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds11 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Osteoboost